阿片类药物对重症患者便秘的影响:元分析
Xuefang Liu1, Ning Yu1, Huaihai Lu1
1Department of Anesthesiology and Intensive Care Unit, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
概括
在重症监护室 (ICU) 中使用阿片类药物显著增加了患者,特别是儿童的便秘风险. 一致地定义ICU便秘对于有效的治疗和未来的研究至关重要.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 类阿片类止痛药经常用于重症监护室 (ICU) 治疗疼痛.
- 阿片类药物诱导的便秘 (OIC) 是一种常见且令人痛苦的副作用,影响患者的康复和舒适.
- 阿片类药物对重症患者便秘风险的确切影响需要进一步澄清.
研究的目的:
- 在ICU患者中进行元分析,评估阿片类药物使用与便秘之间的关联.
- 通过子组分析,探索影响这种关系的因素.
主要方法:
- 通过全面的数据库搜索发现的研究的系统审查和元分析 (PubMed,Embase,Cochrane图书馆,CNKI,万芳数据).
- 包括包括2264名患者的7项研究.
- 应用随机或固定效应模型,并进行子组和灵敏度分析,以评估异质性和稳定性.
主要成果:
- 在ICU患者中服用阿片类药物与便秘风险增加14%有关 (RR=1.14,95% CI=1.05-1.24).
- 亚组分析显示,便秘的定义,阿片类型,研究设计和患者年龄 (特别是儿童) 显著改变了这种风险.
- 敏感性分析证实了整体调查结果的可靠性.
结论:
- 阿片类药物在重症患者中显著增加便秘风险,对儿科患者有显著的影响.
- 在ICU环境中对便秘的定义对观察到的与阿片类药物使用的关系产生了重大影响.
- 对ICU便秘的标准化定义和基于时间的治疗策略是必要的,以及进一步的前性研究.
相关概念视频
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
247
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
247
Analgesia and Pain Management
657
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
657
Opioid Analgesics: Synthetic and Semisynthetic Opioids
335
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
335
Opioid Analgesics: Morphine and Other Natural Cogeners
291
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
291
Drugs for Treatment of Constipation-Predominant IBS
210
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
210
Drugs for Treatment of Diarrhea-Predominant IBS
213
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
213


